Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article.

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a new ...

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now discovered a molecular-level resistance mechanism that begins to take hold as ...

A schematic diagram showing the significant contribution of SCoV2-induced altered mitochondrial dynamics and mitochondrial EGFR translocation in sustaining viral propagation. First, SCOV2 RNA and ...

Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage oncology company developing therapies that target families of oncogenic mutations in patients with cancer. Cullinan Therapeutics, Inc. (CGEM ...

Niigata, Japan—Scientists have made significant progress in understanding the signals involved in regulating oral keratinocyte cell motility and proliferative capacity, offering new insights into ...

The Prescription Drug User Fee Act target date has been set for the third quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...